Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai

Table 3

Multivariate analysis of resistance to second-line drugs in longer/shorter diagnostic delays.

Diagnostic delays (days)	Adjusted OR (95% CI) for a delay longer than median days
	Resistance to SLDs	Resistance to Ofx	Resistance to Am/Km	Resistance to Cm	XDR-TB
Total delay in DST completion; (>136 versus ≤136)	2.22 (1.19–4.11)	2.03 (1.05–3.93)	1.13 (0.52–2.47)	1.39 (0.66–2.91)	1.22 (0.53–2.84)
Delay in TB diagnosis; (>33 versus ≤33)	0.84 (0.47–1.51)	0.85 (0.45–1.58)	0.56 (0.26–1.21)	0.66 (0.33–1.35)	0.52 (0.22–1.21)
Health system delay in DST completion; (>92 versus ≤92)	3.44 (1.79–6.61)	2.59 (1.32–5.09)	1.18 (0.54–2.55)	1.65 (0.79–3.45)	1.31 (0.57–3.03)

OR, odds ratio; CI, confidence interval; SLDs, second-line drugs; Ofx, ofloxacin; Am, amikacin; Km, kanamycin; Cm, capreomycin; XDR-TB, extensively drug-resistant tuberculosis; DST, drug susceptibility testing.
ORs were adjusted for age at diagnosis (continuous), sex, residence, level of TB hospital, and previous TB history.
.
.